Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atorvastatin with Endocrine Therapy in Advanced Breast Cancer
NCT02958852Phase 2Completed
- Sponsor
- Skåne University Hospital
- Start
- Jan 2025
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of atorvastatin in breast cancer (3 arms), sponsored by Skåne University Hospital. Primary endpoint: Clinical Benefit Rate at 6 months. Started Jan 2025; status: completed.
02
Drugs
atorvastatin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02958852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02958852.